Neurogene公布Ngn-401基因疗法治疗雷特综合征1/2期试验积极长期临床数据

美股速递06-29

Neurogene公司公布了其Ngn-401基因疗法用于治疗雷特综合征的1/2期临床试验的积极长期数据。该结果表明，该疗法在延长随访期内持续展现出良好的安全性与耐受性特征，为患者带来了持久的临床获益希望。数据的发布进一步增强了该创新疗法在应对这一严重神经发育障碍方面的潜力，为后续的临床开发奠定了坚实基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1155830354?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-29 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155830354","market":"us","top_or_hot":-1,"title":"Neurogene公布Ngn-401基因疗法治疗雷特综合征1/2期试验积极长期临床数据","media":"美股速递","content":"<p>Neurogene公司公布了其Ngn-401基因疗法用于治疗雷特综合征的1/2期临床试验的积极长期数据。该结果表明，该疗法在延长随访期内持续展现出良好的安全性与耐受性特征，为患者带来了持久的临床获益希望。数据的发布进一步增强了该创新疗法在应对这一严重神经发育障碍方面的潜力，为后续的临床开发奠定了坚实基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurogene公布Ngn-401基因疗法治疗雷特综合征1/2期试验积极长期临床数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurogene公布Ngn-401基因疗法治疗雷特综合征1/2期试验积极长期临床数据\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-29 19:01 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neurogene公司公布了其Ngn-401基因疗法用于治疗雷特综合征的1/2期临床试验的积极长期数据。该结果表明，该疗法在延长随访期内持续展现出良好的安全性与耐受性特征，为患者带来了持久的临床获益希望。数据的发布进一步增强了该创新疗法在应对这一严重神经发育障碍方面的潜力，为后续的临床开发奠定了坚实基础。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NGNE","symbol_name":"NEUROGENE INC","start_time":0,"source_url":"","article_id":"1155830354","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155830354","pubTimestamp":1782730884,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Neurogene公司公布了其Ngn-401基因疗法用于治疗雷特综合征的1/2期临床试验的积极长期数据。该结果表明，该疗法在延长随访期内持续展现出良好的安全性与耐受性特征，为患者带来了持久的临床获益希望。数据的发布进一步增强了该创新疗法在应对这一严重神经发育障碍方面的潜力，为后续的临床开发奠定了坚实基础。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NGNE":"NEUROGENE INC","BK4139":"生物科技"},"translate_title":"Neurogene Announces Positive Long-Term Clinical Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGNE":1},"content_text":"Neurogene公司公布了其Ngn-401基因疗法用于治疗雷特综合征的1/2期临床试验的积极长期数据。该结果表明，该疗法在延长随访期内持续展现出良好的安全性与耐受性特征，为患者带来了持久的临床获益希望。数据的发布进一步增强了该创新疗法在应对这一严重神经发育障碍方面的潜力，为后续的临床开发奠定了坚实基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155830354","isCrawlerRequest":true}